Literature DB >> 11282421

FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition.

M J Cross1, L Claesson-Welsh.   

Abstract

Angiogenic growth factors such as fibroblast growth factors (FGFs) and vascular endothelial growth factors (VEGFs) are currently targets of intense efforts to inhibit deregulated blood vessel formation in diseases such as cancer. FGFs and VEGFs exert their effects via specific binding to cell surface-expressed receptors equipped with tyrosine kinase activity. Activation of the receptor kinase activity allows coupling to downstream signal transduction pathways that regulate proliferation, migration and differentiation of endothelial cells. Inhibitors of FGF and VEGF signalling are currently in clinical trials. In this article, the current knowledge of FGF- and VEGF-induced signal transduction that leads to specific biological responses will be summarized. Furthermore, the manner in which this knowledge is being exploited to regulate angiogenesis will be discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11282421     DOI: 10.1016/s0165-6147(00)01676-x

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  269 in total

1.  The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells.

Authors:  Michael J Cross; Lingge Lu; Peetra Magnusson; Daniel Nyqvist; Kristina Holmqvist; Michael Welsh; Lena Claesson-Welsh
Journal:  Mol Biol Cell       Date:  2002-08       Impact factor: 4.138

2.  Reduced mobility of fibroblast growth factor (FGF)-deficient myoblasts might contribute to dystrophic changes in the musculature of FGF2/FGF6/mdx triple-mutant mice.

Authors:  Petra Neuhaus; Svetlana Oustanina; Tomasz Loch; Marcus Krüger; Eva Bober; Rosanna Dono; Rolf Zeller; Thomas Braun
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

Review 3.  Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast.

Authors:  A Rice; C M Quinn
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

Review 4.  Cardiac cell therapy: boosting mesenchymal stem cells effects.

Authors:  E Samper; A Diez-Juan; J A Montero; P Sepúlveda
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

Review 5.  Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis.

Authors:  André L Mihaljevic; Christoph W Michalski; Helmut Friess; Jörg Kleeff
Journal:  Langenbecks Arch Surg       Date:  2010-03-18       Impact factor: 3.445

Review 6.  miRNAs as therapeutic targets in ischemic heart disease.

Authors:  Robert J A Frost; Eva van Rooij
Journal:  J Cardiovasc Transl Res       Date:  2010-03-30       Impact factor: 4.132

7.  Self-assembling vascular endothelial growth factor nanoparticles improve function in spinocerebellar ataxia type 1.

Authors:  Yuan-Shih Hu; Jeehaeh Do; Chandrakanth Reddy Edamakanti; Ameet R Kini; Marco Martina; Samuel I Stupp; Puneet Opal
Journal:  Brain       Date:  2019-02-01       Impact factor: 13.501

8.  Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding.

Authors:  Gerdy B ten Dam; Els M A van de Westerlo; Anurag Purushothaman; Radu V Stan; Johan Bulten; Fred C G J Sweep; Leon F Massuger; Kazuyuki Sugahara; Toin H van Kuppevelt
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

Review 9.  Current status and future prospect of FSHD region gene 1.

Authors:  Arman Kunwar Hansda; Ankit Tiwari; Manjusha Dixit
Journal:  J Biosci       Date:  2017-06       Impact factor: 1.826

10.  Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury.

Authors:  Alexander J Leedom; Aaron B Sullivan; Baiyan Dong; Denise Lau; Karsten Gronert
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.